Daratumumab, sold under the brand name Darzalex among others, is an anti-cancer monoclonal antibody medication. It binds to CD38, which is overexpressed in multiple myeloma cells. From Wikipedia
Robust oncology growth paired with medtech gains has underpinned J&J’s decision to lift its full-year guidance.
